Centrica plc

Commencement of next tranche of share buyback programme

In its 2024 Preliminary Results on 20 February 2025, Centrica plc (the "Company") announced a further £500 million extension of its share buyback programme (the "2025 Extension"), taking the total programme to £2.0 billion.

Following the successful completion of the first £250 million tranche of the 2025 Extension on 19 September 2025, the Company today announces the entry into an irrevocable arrangement with J.P. Morgan Securities plc ("JPM") (acting as riskless principal) to conduct the repurchases in respect of the second and final £250 million tranche of the 2025 Extension (the "Second Tranche") on its behalf and to make trading decisions in respect of the Second Tranche independently of the Company.

Repurchases in respect of the Second Tranche will commence on 22 September 2025 and will end no later than 16 January 2026, to buy back ordinary shares of 6 ¹⁴/₈₁ pence each (the "Shares") up to an aggregate maximum consideration of £250 million (exclusive of associated fees, expenses and stamp duty), representing an amount equal to the aggregate value of approximately 3% of the Company's issued share capital at the share price as at close of business on 19 September 2025.

JPM may effect purchases of Shares under the Second Tranche on the London Stock Exchange and/or other trading venues¹ for subsequent purchase by the Company. Purchases by the Company will be treated as being made on the London Stock Exchange. The Company intends that any shares purchased will be cancelled, held in treasury, or used for the purposes of employee share schemes.

The purpose of the 2025 Extension is to reduce the capital of the Company.

Any share purchases will be carried out in accordance with certain pre-set parameters. The maximum number of ordinary shares which may be purchased by the Company under the Second Tranche is 503,096,162 shares, being the maximum number of Shares pursuant to the authority granted by shareholders at the Company's Annual General Meeting held on 8 May 2025.

The Second Tranche will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014/EU (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), the Commission Delegated Regulation 2016/1052/EU (as in force in the UK and as amended by the FCA's Technical Standards (Market Abuse Regulation) (EU Exit) Instrument 2019) and in accordance with Chapter 9 of the UK Listing Rules. No repurchases will be made in respect of the Company's American Depositary Receipts.

The Company will make further announcements in due course following any repurchase of Shares. There is no guarantee that the Second Tranche will be implemented in full or that any Shares will be bought back by the Company.

Notes:

1. CBOE Europe Limited (CBOE UK), Turquoise or Aquis.

Enquiries:

Investors and Analysts

Email: [email protected]

Media

Telephone: 01784 843000

Email: [email protected]

END

Centrica plc is listed on the London Stock Exchange (CNA)

Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654

Legal Entity Identifier number: E26EDV109X6EEPBKVH76

ISIN number: GB00B033F229